A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Launched by NATIONAL CANCER INSTITUTE (NCI) · Oct 19, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called zotiraciclib to see if it can help people with a specific type of brain tumor known as recurrent diffuse gliomas, especially those with certain gene mutations called IDH1 or IDH2. These tumors tend to come back after treatment and are known to be aggressive, so researchers are looking for new and better ways to treat them.

To participate in the trial, individuals must be at least 15 years old, have been diagnosed with a diffuse glioma that has returned after treatment, and have the IDH1 or IDH2 mutations. Participants will take zotiraciclib in capsule form at home on specific days over a 28-day cycle. They will also attend regular clinic visits for physical exams, blood tests, and brain scans to monitor their health and the effects of the treatment. Throughout the trial, participants will keep a diary to track their medication doses. This study is currently recruiting participants and aims to find out if zotiraciclib can be an effective treatment for this challenging condition.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Participants must have diffuse glioma, WHO grades 2-4, histologically confirmed by Laboratory of Pathology, NCI.
• • IDH1 or IDH2 mutation status confirmed by TSO500 performed in LP, NCI or prior documentation of IDH1 or IDH2 mutation status
• • Participants must have received prior treatment (e.g., radiation, conventional chemotherapy) prior to disease progression.
• • Participants must have recurrent disease, proven histologically or by imaging studies
• • Participants who have undergone prior surgical resection are eligible for enrollment to cohorts 1-4.
• • Age \>15 years
• • Karnofsky \>70%
• * Participants must have adequate organ and marrow function as defined below:
• • leukocytes \>=3,000/microliter
• • absolute neutrophil count (ANC) \>=1,500/microliter
• • platelets \>100,000/microliter
• • total bilirubin \<=2x ULN (ULN 1.3 mg/dl) except for participants with Gilbert Syndrome
• • AST \< 3x ULN (ULN 34U/L)
• • ALT \< 3x ULN (ULN 55U/L)
• • serum creatinine \< 1.5 mg/dL
• • calculated creatinine clearance by CKD-EPI equation \> 60 cc/min
• • Participants must have recovered from the adverse effects of prior therapy to grade 2 or less (per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0)
• • Individuals of child-bearing potential (IOCBP) and men must agree to use highly effective contraception (hormonal, intrauterine device (IUD), abstinence, tube ligation, partner has had a previous vasectomy) at the study entry, for the duration of study treatment, and up to 3 months after the last dose of zotiraciclib
• • Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 3 months after study treatment discontinuation
• • Participants must be scheduled for brain tumor biopsy or surgical resection at NIH (Cohort 5 only)
• • The ability of a participant, parent or legal guardian of minor participant to understand and the willingness to sign a written informed consent document. No Legally Authorized Representative can provide initial consent.
• EXCLUSION CRITERIA:
• • More than one prior disease relapse (WHO grade 3-4) or more than two prior disease relapses (WHO grade 2) for Phase II only. For Phase I enrollment, there are no limits on the number of prior recurrences.
• * Prior therapy with:
• • any investigational agent (including IDH mutant inhibitor) and/or standard of care cytotoxic therapy within 28 days prior to treatment initiation
• • vincristine within 14 days prior to treatment initiation
• • nitrosoureas within 42 days prior to treatment initiation
• • procarbazine within 21 days prior to treatment initiation
• • non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, within 7 days prior to treatment initiation
• • surgery within 14 days prior to treatment initiation
• • radiation therapy within 30 days prior to treatment initiation
• • bevacizumab for tumor treatment. Note: participants who received bevacizumab for symptom management, including but not limited to cerebral edema, or pseudo progression can be enrolled
• • Prolonged QTc \>470ms as calculated by correction formula on screening electrocardiogram (ECG) (QTCf can be used; QTCb can be used for participants with sinus bradycardia) )
• • Prior invasive malignancies within the past 3 years prior to study treatment initiation (with the exception of non-melanoma skin cancers, carcinoma in situ of the cervix, melanoma in situ, or any localized cancer for whom the systemic standard of care therapy is not required)
• • History of allergic reactions attributed to compounds of similar chemical composition to zotiraciclib, such as flavopiridol
• • Pregnancy (confirmed with beta-HCG serum or urine pregnancy test performed at screening)
• • Uncontrolled intercurrent illness or social situations that would limit compliance with study requirements
• • Uncontrolled primary diabetes mellitus